Human	B-cell_type
CD4	I-cell_type
lymphocytes	I-cell_type
specifically	O
recognize	O
a	O
peptide	O
representing	O
the	O
fusion	O
region	O
of	O
the	O
hybrid	B-protein
protein	I-protein
pml/RAR	B-protein
alpha	I-protein
present	O
in	O
acute	B-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

Fusion	O
proteins	O
present	O
in	O
leukemic	B-cell_type
cells	I-cell_type
frequently	O
contain	O
a	O
new	O
amino	O
acid	O
at	O
the	O
fusion	B-protein
point	I-protein
.	O

We	O
tested	O
whether	O
a	O
peptide	O
(	O
BCR1/25	O
)	O
encompassing	O
the	O
fusion	B-protein
region	I-protein
of	O
the	O
hybrid	O
molecule	O
pml/RAR	B-protein
alpha	I-protein
,	O
which	O
is	O
selectively	O
expressed	O
by	O
acute	B-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
(	I-cell_type
APL	I-cell_type
)	I-cell_type
cells	I-cell_type
,	O
can	O
be	O
recognized	O
by	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
in	O
vitro	O
.	O

CD4+	B-cell_type
lymphocytes	I-cell_type
,	O
at	O
both	O
polyclonal	O
and	O
clonal	O
level	O
,	O
recognized	O
peptide	O
BCR1/25	O
in	O
an	O
HLA-DR	B-protein
--	O
restricted	O
fashion	O
on	O
presentation	O
by	O
autologous	B-cell_type
antigen-presenting	I-cell_type
cell	I-cell_type
(	O
APC	B-cell_type
)	O
or	O
by	O
APC	B-cell_type
expressing	O
the	O
HLA-DR11	B-protein
restricting	I-protein
molecule	I-protein
.	O

Control	O
peptides	O
corresponding	O
to	O
the	O
normal	O
pml	B-protein
and	O
RAR	B-protein
alpha	I-protein
proteins	I-protein
were	O
not	O
recognized	O
.	O

One	O
clone	O
(	O
DEG5	B-cell_line
)	O
also	O
exerted	O
a	O
high	O
and	O
specific	O
cytotoxicity	O
against	O
autologous	B-cell_line
cells	I-cell_line
pulsed	O
with	O
BCR1/25	O
.	O

The	O
autologous	B-cell_line
DE	I-cell_line
LCL	I-cell_line
containing	O
a	O
transduced	O
pml/RAR	B-DNA
alpha	I-DNA
fusion	I-DNA
gene	I-DNA
and	O
expressing	O
a	O
bcr1	O
type	O
of	O
the	O
pml/RAR	B-protein
alpha	I-protein
hybrid	O
protein	O
induced	O
the	O
proliferation	O
of	O
DE	B-cell_line
anti-BCR1/25	I-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
.	O

It	O
is	O
concluded	O
that	O
the	O
bcr1	B-protein
type-pml/RAR	I-protein
alpha	I-protein
fusion	I-protein
protein	I-protein
of	O
APL	B-cell_line
contains	O
an	O
antigenic	O
site	O
,	O
absent	O
from	O
the	O
normal	O
parent	O
molecules	O
and	O
recognized	O
by	O
human	B-cell_line
CD4+	I-cell_line
lymphocytes	I-cell_line
.	O

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

Human	NULL
CD4	NULL
Lymphocytes	NULL
Specifically	NULL
Recognize	NULL
a	NULL
Peptide	NULL
Representing	NULL
the	NULL
Fusion	NULL
Region	NULL
of	NULL
the	NULL
Hybrid	NULL
Protein	NULL
pml/RARa	NULL
«	NULL
Present	NULL
in	NULL
Acute	NULL
Promyelocytic	NULL
Leukemia	NULL
Cells	NULL
By	NULL
Carlo	NULL
Gambacorti-Passerini	NULL
,	NULL
Francesco	NULL
Grignani	NULL
,	NULL
Flavio	NULL
Arienti	NULL
,	NULL
Pier	NULL
Paolo	NULL
Pandolfi	NULL
,	NULL
Pier	NULL
Giuseppe	NULL
Pelicci	NULL
,	NULL
and	NULL
Giorgio	NULL
Parmiani	NULL
Fusion	NULL
proteins	NULL
present	NULL
in	NULL
leukemic	NULL
cells	NULL
frequently	NULL
contain	NULL
a	NULL
new	NULL
amino	NULL
acid	NULL
at	NULL
the	NULL
fusion	NULL
point	NULL
.	NULL

We	NULL
tested	NULL
whether	NULL
a	NULL
peptide	NULL
(	NULL
BCR1/25	NULL
)	NULL
encompassing	NULL
the	NULL
fusion	NULL
region	NULL
of	NULL
the	NULL
hybrid	NULL
molecule	NULL
pml/RARa	NULL
,	NULL
which	NULL
is	NULL
selectively	NULL
expressed	NULL
by	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
cells	NULL
,	NULL
can	NULL
be	NULL
recognized	NULL
by	NULL
human	NULL
T	NULL
lymphocytes	NULL
in	NULL
vitro	NULL
.	NULL

CD4*	NULL
lympho-cytes	NULL
,	NULL
at	NULL
both	NULL
polyclonal	NULL
and	NULL
clonal	NULL
level	NULL
,	NULL
recognized	NULL
peptide	NULL
BCR1/25	NULL
in	NULL
an	NULL
HLA-DR-restricted	NULL
fashion	NULL
on	NULL
presentation	NULL
by	NULL
autologous	NULL
antigen-presenting	NULL
cell	NULL
(	NULL
APC	NULL
)	NULL
or	NULL
by	NULL
APC	NULL
expressing	NULL
the	NULL
HLA-DR11	NULL
restricting	NULL
molecule	NULL
.	NULL

Control	NULL
peptides	NULL
corresponding	NULL
to	NULL
the	NULL
normal	NULL
pml	NULL
and	NULL
RAR	NULL
proteins	NULL
SPECIFIC	NULL
15:17	NULL
chromosomal	NULL
translocation	NULL
is	NULL
present	NULL
in	NULL
80	NULL
%	NULL
to	NULL
90	NULL
%	NULL
of	NULL
cases	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
.	NULL
``	NULL

One	NULL
product	NULL
of	NULL
this	NULL
translocation	NULL
,	NULL
which	NULL
is	NULL
considered	NULL
to	NULL
play	NULL
a	NULL
major	NULL
role	NULL
in	NULL
promyelocyte	NULL
transformation	NULL
,	NULL
is	NULL
represented	NULL
by	NULL
a	NULL
hybrid	NULL
protein	NULL
in	NULL
which	NULL
the	NULL
product	NULL
of	NULL
the	NULL
third	NULL
exon	NULL
of	NULL
the	NULL
RARa	NULL
gene	NULL
,	NULL
located	NULL
on	NULL
chromosome	NULL
17	NULL
,	NULL
is	NULL
fused	NULL
to	NULL
the	NULL
amino	NULL
terminal	NULL
portion	NULL
of	NULL
another	NULL
Zn	NULL
finger	NULL
protein	NULL
named	NULL
pml	NULL
.	NULL

``	NULL
~	NULL
Although	NULL
different	NULL
types	NULL
of	NULL
fusion	NULL
are	NULL
present	NULL
,	NULL
one	NULL
of	NULL
them	NULL
(	NULL
named	NULL
ber1	NULL
)	NULL
is	NULL
most	NULL
frequently	NULL
observed	NULL
in	NULL
APL	NULL
cells	NULL
.	NULL

*	NULL
The	NULL
fusion	NULL
protein	NULL
resulting	NULL
from	NULL
this	NULL
translocation	NULL
thus	NULL
contains	NULL
two	NULL
sets	NULL
of	NULL
amino	NULL
acids	NULL
that	NULL
normally	NULL
do	NULL
not	NULL
belong	NULL
to	NULL
the	NULL
same	NULL
protein	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
the	NULL
amino	NULL
acid	NULL
corresponding	NULL
to	NULL
the	NULL
fusion	NULL
point	NULL
(	NULL
Ala	NULL
)	NULL
differs	NULL
from	NULL
the	NULL
corresponding	NULL
ones	NULL
on	NULL
both	NULL
the	NULL
normal	NULL
RARa	NULL
(	NULL
Thr	NULL
)	NULL
and	NULL
pml	NULL
(	NULL
Glu	NULL
)	NULL
proteins	NULL
.	NULL

*	NULL
``	NULL
The	NULL
reason	NULL
for	NULL
this	NULL
``	NULL
new	NULL
``	NULL
amino	NULL
acid	NULL
derives	NULL
from	NULL
the	NULL
hybrid	NULL
nature	NULL
of	NULL
the	NULL
triplet	NULL
(	NULL
GCC	NULL
)	NULL
of	NULL
bases	NULL
coding	NULL
for	NULL
that	NULL
amino	NULL
acid	NULL
,	NULL
with	NULL
one	NULL
base	NULL
(	NULL
G	NULL
)	NULL
donated	NULL
by	NULL
the	NULL
pml	NULL
gene	NULL
and	NULL
the	NULL
two	NULL
others	NULL
(	NULL
CC	NULL
)	NULL
originating	NULL
from	NULL
RARa	NULL
«	NULL
.	NULL

It	NULL
is	NULL
known	NULL
that	NULL
a	NULL
single	NULL
amino	NULL
acidic	NULL
difference	NULL
is	NULL
sufficient	NULL
to	NULL
generate	NULL
a	NULL
new	NULL
antigenic	NULL
site	NULL
``	NULL
;	NULL
therefore	NULL
,	NULL
the	NULL
ber|	NULL
type	NULL
of	NULL
the	NULL
pml/RARa	NULL
«	NULL
fusion	NULL
protein	NULL
could	NULL
contain	NULL
a	NULL
new	NULL
antigenic	NULL
site	NULL
,	NULL
absent	NULL
from	NULL
the	NULL
two	NULL
normal	NULL
parent	NULL
proteins	NULL
that	NULL
originate	NULL
the	NULL
fusion	NULL
molecule	NULL
.	NULL

It	NULL
is	NULL
also	NULL
known	NULL
that	NULL
antigens	NULL
are	NULL
presented	NULL
to	NULL
T	NULL
lymphocytes	NULL
in	NULL
the	NULL
form	NULL
of	NULL
small	NULL
peptides	NULL
associated	NULL
with	NULL
HLA	NULL
class	NULL
I	NULL
or	NULL
II	NULL
molecules	NULL
.	NULL
``	NULL

''	NULL
``	NULL
To	NULL
test	NULL
the	NULL
hypothesis	NULL
that	NULL
the	NULL
pral/RAR	NULL
«	NULL
a	NULL
protein	NULL
contains	NULL
a	NULL
new	NULL
antigen	NULL
recognized	NULL
by	NULL
T	NULL
cells	NULL
,	NULL
a	NULL
25-mer	NULL
peptide	NULL
(	NULL
BCR1/	NULL
25	NULL
)	NULL
,	NULL
encompassing	NULL
the	NULL
fusion	NULL
point	NULL
of	NULL
the	NULL
pml/RARa	NULL
«	NULL
fusion	NULL
protein	NULL
(	NULL
berl	NULL
type	NULL
)	NULL
,	NULL
was	NULL
synthesized	NULL
,	NULL
purified	NULL
by	NULL
high-per-formance	NULL
liquid	NULL
chromatography	NULL
(	NULL
HPLC	NULL
)	NULL
,	NULL
and	NULL
used	NULL
to	NULL
stimulate	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
obtained	NULL
from	NULL
healthy	NULL
donors	NULL
.	NULL

We	NULL
report	NULL
here	NULL
that	NULL
human	NULL
CD4	NULL
lymphocytes	NULL
can	NULL
specifically	NULL
recognize	NULL
in	NULL
an	NULL
HLA-restricted	NULL
way	NULL
both	NULL
peptide	NULL
BCR	NULL
1/	NULL
25	NULL
and	NULL
autologous	NULL
cells	NULL
expressing	NULL
the	NULL
berl	NULL
type	NULL
pml/RARa	NULL
fusion	NULL
protein	NULL
in	NULL
vitro	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Peptides	NULL
.	NULL

-	NULL
The	NULL
peptides	NULL
used	NULL
in	NULL
this	NULL
study	NULL
are	NULL
the	NULL
following	NULL
:	NULL
BCR1/	NULL
25	NULL
,	NULL
NSNHVASGAGEAAIETQSSSSEEIV	NULL
;	NULL
BCR3	NULL
,	NULL
ITQGKAIE-TQSSSSEEIV	NULL
;	NULL
pml	NULL
,	NULL
NSNHVASGAGEAEERVVVISSSED	NULL
;	NULL
ras	NULL
,	NULL
KLVVVGAGGVGK	NULL
;	NULL
b3	NULL
,	NULL
SATGFKQSSKALQRPVASD	NULL
.	NULL

They	NULL
Blood	NULL
,	NULL
Vol	NULL
81	NULL
,	NULL
No	NULL
5	NULL
(	NULL
March	NULL
1	NULL
}	NULL
,	NULL
1993	NULL
:	NULL
pp	NULL
1369-1375	NULL
were	NULL
not	NULL
recognized	NULL
.	NULL

One	NULL
clone	NULL
(	NULL
DEGS	NULL
)	NULL
also	NULL
exerted	NULL
a	NULL
high	NULL
and	NULL
specific	NULL
cytotoxicity	NULL
against	NULL
autologous	NULL
cells	NULL
pulsed	NULL
with	NULL
BCR1/25	NULL
.	NULL

The	NULL
autologous	NULL
DE	NULL
LCL	NULL
containing	NULL
a	NULL
trans-duced	NULL
pmI/RAR	NULL
«	NULL
fusion	NULL
gene	NULL
and	NULL
expressing	NULL
a	NULL
beri	NULL
type	NULL
of	NULL
the	NULL
pmi	NULL
{	NULL
i/RARa	NULL
«	NULL
hybrid	NULL
protein	NULL
induced	NULL
the	NULL
proliferation	NULL
of	NULL
DE	NULL
anti-BCR1/25	NULL
T	NULL
cell	NULL
clones	NULL
.	NULL

It	NULL
is	NULL
concluded	NULL
that	NULL
the	NULL
beri	NULL
type-pmi/RARa	NULL
«	NULL
fusion	NULL
protein	NULL
of	NULL
APL	NULL
contains	NULL
an	NULL
antigenic	NULL
site	NULL
,	NULL
absent	NULL
from	NULL
the	NULL
normal	NULL
parent	NULL
molecules	NULL
and	NULL
recognized	NULL
by	NULL
human	NULL
CD4*	NULL
lymphocytes	NULL
.	NULL

©	NULL
1993	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

represent	NULL
the	NULL
fusion	NULL
region	NULL
of	NULL
the	NULL
pmIl/RARa	NULL
protein	NULL
(	NULL
BCR	NULL
1/25	NULL
and	NULL
BCR3	NULL
,	NULL
in	NULL
which	NULL
the	NULL
same	NULL
RARa-derived	NULL
sequence	NULL
joins	NULL
a	NULL
different	NULL
pml	NULL
sequence	NULL
)	NULL
and	NULL
of	NULL
the	NULL
ber/abl	NULL
(	NULL
b3	NULL
)	NULL
protein	NULL
(	NULL
an	NULL
unrelated	NULL
fusion	NULL
protein	NULL
present	NULL
in	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
cells	NULL
)	NULL
.	NULL

The	NULL
remaining	NULL
peptides	NULL
represent	NULL
part	NULL
of	NULL
the	NULL
normal	NULL
pml	NULL
protein	NULL
(	NULL
pm	NULL
!	NULL
)	NULL

corresponding	NULL
to	NULL
the	NULL
fusion	NULL
region	NULL
of	NULL
the	NULL
berl	NULL
-type	NULL
pml/RARa	NULL
protein	NULL
or	NULL
part	NULL
of	NULL
a	NULL
mutated	NULL
ras	NULL
protein	NULL
(	NULL
ras	NULL
)	NULL
.	NULL

The	NULL
peptides	NULL
were	NULL
synthesized	NULL
at	NULL
the	NULL
University	NULL
of	NULL
Wisconsin	NULL
Biotechnology	NULL
Center	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
,	NULL
or	NULL
by	NULL
Neosystem	NULL
SA	NULL
,	NULL
Strasbourg	NULL
,	NULL
France	NULL
,	NULL
and	NULL
purified	NULL
by	NULL
HPLC	NULL
to	NULL
a	NULL
minimum	NULL
purity	NULL
of	NULL
95	NULL
%	NULL
.	NULL

Single	NULL
impurities	NULL
never	NULL
exceeded	NULL
1	NULL
%	NULL
.	NULL

(	NULL
The	NULL
sequences	NULL
of	NULL
these	NULL
peptides	NULL
were	NULL
derived	NULL
from	NULL
references	NULL
4	NULL
,	NULL
5	NULL
,	NULL
11	NULL
,	NULL
and	NULL
12	NULL
)	NULL
.	NULL

PBMC	NULL
.	NULL

-	NULL
PBMC	NULL
were	NULL
obtained	NULL
from	NULL
peripheral	NULL
blood	NULL
by	NULL
centrif-ugation	NULL
on	NULL
Ficoll	NULL
gradients	NULL
and	NULL
immediately	NULL
used	NULL
or	NULL
frozen	NULL
.	NULL

Lymphoblastoid	NULL
cell	NULL
lines	NULL
(	NULL
LCL	NULL
)	NULL
.	NULL

PBMC	NULL
(	NULL
10	NULL
'	NULL
cells	NULL
)	NULL
were	NULL
incubated	NULL
overnight	NULL
with	NULL
3	NULL
mL	NULL
of	NULL
the	NULL
supernatant	NULL
from	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
-producing	NULL
line	NULL
B95.8	NULL
(	NULL
a	NULL
gift	NULL
of	NULL
Dr	NULL
Paul	NULL
Sondel	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
and	NULL
cultured	NULL
in	NULL
RPMI	NULL
+	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
.	NULL

Cyclosporine	NULL
(	NULL
2	NULL
ug/mL	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cultures	NULL
during	NULL
the	NULL
first	NULL
month	NULL
.	NULL

LCL	NULL
were	NULL
used	NULL
after	NULL
2	NULL
months	NULL
of	NULL
culture	NULL
.	NULL

DR	NULL
phenotype	NULL
of	NULL
LCL	NULL
.	NULL

-	NULL
This	NULL
assay	NULL
was	NULL
performed	NULL
on	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
PCR	NULL
)	NULL
-amplified	NULL
DNA	NULL
samples	NULL
by	NULL
using	NULL
sequence-specific	NULL
oligonucleotides	NULL
.	NULL
``	NULL

Production	NULL
of	NULL
a	NULL
pml/RARa	NULL
retroviral	NULL
vector	NULL
and	NULL
infection	NULL
of	NULL
DE	NULL
LCL	NULL
cells	NULL
.	NULL

A	NULL
pml/RARa	NULL
clone	NULL
from	NULL
position	NULL
652	NULL
to	NULL
position	NULL
3101	NULL
of	NULL
the	NULL
published	NULL
sequence*	NULL
was	NULL
inserted	NULL
into	NULL
the	NULL
£EcoR	NULL
1	NULL
site	NULL
of	NULL
the	NULL
plasmid	NULL
LXSN'*	NULL
to	NULL
produce	NULL
the	NULL
retroviral	NULL
plasmid	NULL
pLSPRSN	NULL
.	NULL

In	NULL
this	NULL
clone	NULL
the	NULL
reading	NULL
frame	NULL
starts	NULL
from	NULL
ATG	NULL
codon	NULL
at	NULL
position	NULL
715	NULL
and	NULL
ends	NULL
at	NULL
the	NULL
TGA	NULL
stop	NULL
codon	NULL
at	NULL
position	NULL
2854	NULL
,	NULL
encoding	NULL
a	NULL
protein	NULL
with	NULL
the	NULL
expected	NULL
molecular	NULL
weight	NULL
of	NULL
78.8	NULL
Kd	NULL
.	NULL

It	NULL
contains	NULL
most	NULL
of	NULL
From	NULL
the	NULL
Division	NULL
of	NULL
Experimental	NULL
Oncology	NULL
D	NULL
,	NULL
Istituto	NULL
Nazionale	NULL
Tumori	NULL
,	NULL
Milan	NULL
,	NULL
and	NULL
the	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Perugia	NULL
,	NULL
Perugia	NULL
,	NULL
Italy	NULL
.	NULL

Submitted	NULL
July	NULL
30	NULL
,	NULL
1992	NULL
;	NULL
accepted	NULL
November	NULL
2	NULL
,	NULL
1992	NULL
.	NULL

Supported	NULL
in	NULL
part	NULL
by	NULL
the	NULL
Italian	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
(	NULL
AIRC	NULL
)	NULL
and	NULL
the	NULL
Italy-USA	NULL
program	NULL
on	NULL
therapy	NULL
of	NULL
tumors	NULL
(	NULL
no	NULL
.	NULL

531	NULL
23.12.87	NULL
)	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Carlo	NULL
Gambacorti-Passerini	NULL
,	NULL
MD	NULL
,	NULL
Division	NULL
of	NULL
Experimental	NULL
Oncology	NULL
D	NULL
,	NULL
Istituto	NULL
Nazionale	NULL
Tumori	NULL
,	NULL
Via	NULL
Venezian	NULL
1	NULL
,	NULL
20133	NULL
Milano	NULL
,	NULL
Italy	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

©	NULL
1993	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
.	NULL

0006-4971/93/8105-0024	NULL
$	NULL
3.00/0	NULL
1369	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1370	NULL
the	NULL
pmIl/RARa	NULL
fusion	NULL
protein	NULL
,	NULL
including	NULL
the	NULL
pmIl/RARa	NULL
junction	NULL
sequence	NULL
from	NULL
which	NULL
the	NULL
peptide	NULL
BCR1/25	NULL
used	NULL
in	NULL
this	NULL
study	NULL
was	NULL
derived	NULL
.	NULL

The	NULL
production	NULL
of	NULL
a	NULL
helper-free	NULL
retroviral	NULL
vector	NULL
was	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Briefly	NULL
,	NULL
the	NULL
PLSPRSN	NULL
plasmid	NULL
was	NULL
transfected	NULL
into	NULL
W2	NULL
cells	NULL
.	NULL
``	NULL

After	NULL
48	NULL
hours	NULL
the	NULL
W2	NULL
cell	NULL
medium	NULL
containing	NULL
the	NULL
ecotropic	NULL
virus	NULL
was	NULL
collected	NULL
and	NULL
used	NULL
to	NULL
infect	NULL
the	NULL
amphotropic	NULL
packaging	NULL
cell	NULL
line	NULL
PA317	NULL
.	NULL
``	NULL

''	NULL
The	NULL
infected	NULL
PA317	NULL
cells	NULL
were	NULL
selected	NULL
in	NULL
300	NULL
ug/	NULL
mL	NULL
G418	NULL
and	NULL
subcloned	NULL
by	NULL
limiting	NULL
dilution	NULL
.	NULL

The	NULL
clones	NULL
were	NULL
analyzed	NULL
for	NULL
the	NULL
production	NULL
of	NULL
the	NULL
correct	NULL
mRNA	NULL
and	NULL
protein	NULL
by	NULL
Northern	NULL
and	NULL
Western	NULL
blotting	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
virus	NULL
production	NULL
titers	NULL
of	NULL
the	NULL
clones	NULL
expressing	NULL
the	NULL
expected	NULL
protein	NULL
were	NULL
measured	NULL
by	NULL
infecting	NULL
the	NULL
human	NULL
osteosarcoma	NULL
cell	NULL
line	NULL
U2OS	NULL
(	NULL
obtained	NULL
from	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
[	NULL
ATCC	NULL
]	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

A	NULL
PA317	NULL
clone	NULL
producing	NULL
the	NULL
control	NULL
LXSN	NULL
vector	NULL
was	NULL
also	NULL
generated	NULL
with	NULL
the	NULL
same	NULL
procedure	NULL
.	NULL

High-titer	NULL
clones	NULL
of	NULL
LSPRSN	NULL
and	NULL
LXSN	NULL
were	NULL
used	NULL
to	NULL
infect	NULL
target	NULL
cells	NULL
.	NULL

The	NULL
DE	NULL
LCL	NULL
target	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
one	NULL
three-hour	NULL
infection	NULL
cycle	NULL
per	NULL
day	NULL
for	NULL
3	NULL
days	NULL
.	NULL

After	NULL
24	NULL
hours	NULL
from	NULL
the	NULL
last	NULL
infection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
selected	NULL
in	NULL
600	NULL
ug/mL	NULL
G418	NULL
.	NULL

Two	NULL
cell	NULL
lines	NULL
were	NULL
obtained	NULL
and	NULL
named	NULL
DE/PR	NULL
(	NULL
infected	NULL
with	NULL
LSPRSN	NULL
)	NULL
and	NULL
DE/SN	NULL
(	NULL
infected	NULL
with	NULL
LXSN	NULL
)	NULL
.	NULL

The	NULL
production	NULL
of	NULL
the	NULL
PML/RAR	NULL
by	NULL
the	NULL
infected	NULL
cells	NULL
was	NULL
assayed	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

Western	NULL
blotting	NULL
.	NULL

-	NULL
The	NULL
preparation	NULL
of	NULL
cell	NULL
lysates	NULL
and	NULL
the	NULL
methods	NULL
for	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
and	NULL
Western	NULL
blotting	NULL
were	NULL
previously	NULL
described	NULL
.	NULL

'*	NULL
Thirty	NULL
micrograms	NULL
of	NULL
total	NULL
cell	NULL
protein	NULL
were	NULL
resolved	NULL
in	NULL
each	NULL
sample	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
probed	NULL
with	NULL
an	NULL
anti-RARa	NULL
domain	NULL
F	NULL
rabbit	NULL
antiserum	NULL
``	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr	NULL
P	NULL
Chambon	NULL
,	NULL
Strasbourg	NULL
,	NULL
France	NULL
)	NULL
,	NULL
and	NULL
developed	NULL
with	NULL
alkaline	NULL
phos-phatase-conjugated	NULL
secondary	NULL
antibody	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

DR	NULL
transfectants	NULL
.	NULL

-	NULL
Murine	NULL
fibroblasts	NULL
transfected	NULL
with	NULL
human	NULL
DR	NULL
genes	NULL
were	NULL
a	NULL
gift	NULL
from	NULL
Dr	NULL
R.	NULL
Karr	NULL
,	NULL
Monsanto	NULL
Inc	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
,	NULL
``	NULL
and	NULL
from	NULL
Dr	NULL
Julia	NULL
Bodmer	NULL
,	NULL
ICRF	NULL
,	NULL
London	NULL
,	NULL
England	NULL
.	NULL

They	NULL
were	NULL
cultured	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
FCS	NULL
,	NULL
20	NULL
mmol/L	NULL
L-glutamine	NULL
,	NULL
and	NULL
250	NULL
ug/mL	NULL
G418	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
DR	NULL
molecules	NULL
on	NULL
murine	NULL
fibroblasts	NULL
was	NULL
assessed	NULL
by	NULL
indirect	NULL
im-munofluorescence	NULL
with	NULL
D1-12	NULL
MoAb	NULL
and	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
analysis	NULL
.	NULL

In	NULL
vitro	NULL
activation	NULL
.	NULL

-	NULL
PBMC	NULL
were	NULL
seeded	NULL
in	NULL
96-well	NULL
flat-bottom	NULL
plates	NULL
(	NULL
10°	NULL
cells/well	NULL
)	NULL
in	NULL
RPMI	NULL
plus	NULL
5	NULL
%	NULL
human	NULL
serum	NULL
(	NULL
HS	NULL
)	NULL
and	NULL
stimulated	NULL
with	NULL
10°	NULL
autologous	NULL
antigen-presenting	NULL
cells	NULL
(	NULL
APC	NULL
)	NULL
pulsed	NULL
with	NULL
BCR	NULL
1/25	NULL
(	NULL
2	NULL
umol/L	NULL
final	NULL
concentration	NULL
)	NULL
.	NULL

The	NULL
number	NULL
of	NULL
wells	NULL
seeded	NULL
for	NULL
each	NULL
donor	NULL
ranged	NULL
from	NULL
384	NULL
to	NULL
672	NULL
.	NULL

PBMC	NULL
were	NULL
used	NULL
as	NULL
APC	NULL
;	NULL
they	NULL
were	NULL
preincubated	NULL
in	NULL
serum-free	NULL
RPMI	NULL
with	NULL
peptide	NULL
at	NULL
20	NULL
amol/	NULL
L	NULL
for	NULL
2	NULL
hours	NULL
and	NULL
then	NULL
added	NULL
to	NULL
the	NULL
wells	NULL
.	NULL

Recombinant	NULL
interleukin-2	NULL
(	NULL
rIL-2	NULL
,	NULL
10	NULL
U/mL	NULL
,	NULL
corresponding	NULL
to	NULL
60	NULL
IU/mL	NULL
;	NULL
EuroCetus	NULL
BV	NULL
,	NULL
Am-sterdam	NULL
,	NULL
The	NULL
Netherlands	NULL
)	NULL
was	NULL
added	NULL
after	NULL
4	NULL
to	NULL
5	NULL
days	NULL
and	NULL
the	NULL
percent	NULL
of	NULL
HS	NULL
was	NULL
increased	NULL
to	NULL
10	NULL
%	NULL
.	NULL

This	NULL
activation	NULL
cycle	NULL
was	NULL
repeated	NULL
after	NULL
L0	NULL
and	NULL
20	NULL
days	NULL
of	NULL
culture	NULL
using	NULL
irradiated	NULL
(	NULL
400	NULL
cGy	NULL
)	NULL
APC	NULL
(	NULL
XR	NULL
APC	NULL
)	NULL
.	NULL

After	NULL
the	NULL
third	NULL
cycle	NULL
of	NULL
stimulation	NULL
,	NULL
each	NULL
plate	NULL
,	NULL
containing	NULL
2	NULL
to	NULL
5	NULL
%	NULL
10°	NULL
cells/well	NULL
,	NULL
was	NULL
split	NULL
into	NULL
three	NULL
plates	NULL
,	NULL
two	NULL
of	NULL
which	NULL
were	NULL
restimulated	NULL
with	NULL
peptide-pulsed	NULL
APC	NULL
,	NULL
and	NULL
the	NULL
third	NULL
(	NULL
control	NULL
plate	NULL
)	NULL
with	NULL
APC	NULL
alone	NULL
.	NULL

After	NULL
48	NULL
hours	NULL
of	NULL
culture	NULL
,	NULL
one	NULL
of	NULL
the	NULL
plates	NULL
restimulated	NULL
with	NULL
the	NULL
peptide	NULL
and	NULL
the	NULL
control	NULL
plate	NULL
were	NULL
labeled	NULL
with	NULL
'HTdR	NULL
,	NULL
further	NULL
cultured	NULL
for	NULL
18	NULL
hours	NULL
,	NULL
and	NULL
harvested	NULL
.	NULL

Positive	NULL
wells	NULL
were	NULL
identified	NULL
as	NULL
those	NULL
in	NULL
which	NULL
the	NULL
counts	NULL
per	NULL
minute	NULL
were	NULL
>	NULL
2	NULL
times	NULL
the	NULL
counts	NULL
per	NULL
minute	NULL
in	NULL
the	NULL
control	NULL
wells	NULL
in	NULL
two	NULL
consecutive	NULL
experiments	NULL
.	NULL

Lymphocyte	NULL
clones	NULL
.	NULL

-	NULL
Polyclonal	NULL
lines	NULL
were	NULL
cloned	NULL
by	NULL
limiting	NULL
dilution	NULL
(	NULL
1	NULL
cell/well	NULL
)	NULL
in	NULL
96-well	NULL
plates	NULL
(	NULL
U	NULL
bottom	NULL
)	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
autologous	NULL
peptide	NULL
pulsed	NULL
(	NULL
2	NULL
umol/L	NULL
final	NULL
concentration	NULL
)	NULL
XR-APC	NULL
and	NULL
rIL-2	NULL
(	NULL
50	NULL
Cetus	NULL
U/mL	NULL
,	NULL
corresponding	NULL
to	NULL
300	NULL
IU/mL	NULL
)	NULL
.	NULL

The	NULL
growing	NULL
clones	NULL
were	NULL
restimulated	NULL
every	NULL
7	NULL
to	NULL
10	NULL
days	NULL
with	NULL
the	NULL
same	NULL
protocol	NULL
used	NULL
for	NULL
polyclonal	NULL
lines	NULL
(	NULL
autologous	NULL
XR	NULL
,	NULL
800	NULL
cGy	NULL
,	NULL
EBV-transformed	NULL
LCL	NULL
were	NULL
used	NULL
as	NULL
feeder	NULL
cells	NULL
)	NULL
.	NULL

The	NULL
probability	NULL
of	NULL
clonality	NULL
for	NULL
each	NULL
GAMBACORTI-PASSERINI	NULL
ET	NULL
AL	NULL
well	NULL
containing	NULL
growth	NULL
(	NULL
P	NULL
clone	NULL
)	NULL
was	NULL
calculated	NULL
according	NULL
to	NULL
the	NULL
following	NULL
formula®	NULL
``	NULL
:	NULL
P	NULL
clone	NULL
=	NULL
XF	NULL
x	NULL
-	NULL
where	NULL
X	NULL
is	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
seeded	NULL
in	NULL
each	NULL
well	NULL
and	NULL
F	NULL
is	NULL
the	NULL
frequency	NULL
of	NULL
clonogenic	NULL
precursors	NULL
that	NULL
represents	NULL
the	NULL
slope	NULL
of	NULL
the	NULL
regression	NULL
curve	NULL
obtained	NULL
by	NULL
plotting	NULL
the	NULL
In	NULL
of	NULL
the	NULL
percent	NULL
of	NULL
negative	NULL
wells	NULL
against	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
seeded	NULL
per	NULL
well	NULL
.	NULL

Proliferative	NULL
response	NULL
to	NULL
peptides	NULL
.	NULL

T-cell	NULL
clones	NULL
(	NULL
4	NULL
to	NULL
5	NULL
X	NULL
104	NULL
well	NULL
)	NULL
were	NULL
cultured	NULL
for	NULL
48	NULL
hours	NULL
with	NULL
autologous	NULL
irradiated	NULL
(	NULL
800	NULL
cGy	NULL
)	NULL
LCLs	NULL
(	NULL
10°/well	NULL
)	NULL
+	NULL
BCR1/25	NULL
or	NULL
control	NULL
peptides	NULL
,	NULL
incubated	NULL
for	NULL
additional	NULL
18	NULL
hours	NULL
with	NULL
°HTdR	NULL
(	NULL
1	NULL
uCi/well	NULL
)	NULL
,	NULL
and	NULL
harvested	NULL
.	NULL

For	NULL
blocking	NULL
experiments	NULL
,	NULL
MoAbs	NULL
were	NULL
added	NULL
to	NULL
the	NULL
wells	NULL
containing	NULL
the	NULL
XR-LCL	NULL
immediately	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
lymphocytes	NULL
.	NULL

Anti-CD3	NULL
(	NULL
OKT3	NULL
,	NULL
from	NULL
ATCC	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
purified	NULL
antibody	NULL
,	NULL
whereas	NULL
anti-HLA	NULL
class	NULL
I	NULL
(	NULL
W6/32	NULL
,	NULL
from	NULL
ATCC	NULL
)	NULL
or	NULL
II	NULL
(	NULL
anti-DR	NULL
,	NULL
Di-12	NULL
,	NULL
a	NULL
gift	NULL
from	NULL
Dr	NULL
R.	NULL
Accolla	NULL
,	NULL
Verona	NULL
,	NULL
Italy	NULL
)	NULL
MoAbs	NULL
were	NULL
in	NULL
the	NULL
form	NULL
of	NULL
diluted	NULL
ascites	NULL
.	NULL

Cytotoxic	NULL
assay	NULL
.	NULL

This	NULL
assay	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
.	NULL
``	NULL

Target	NULL
cells	NULL
were	NULL
labeled	NULL
with	NULL
Na®	NULL
``	NULL
CrO	NULL
,	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
seeded	NULL
into	NULL
96-well	NULL
microplates	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
lymphocyte	NULL
clones	NULL
at	NULL
different	NULL
effector/target	NULL
(	NULL
E/T	NULL
)	NULL
ratios	NULL
(	NULL
20	NULL
,	NULL
10	NULL
,	NULL
5	NULL
,	NULL
and	NULL
2.5/1	NULL
)	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
200	NULL
gL	NULL
.	NULL

The	NULL
plates	NULL
were	NULL
then	NULL
centrifuged	NULL
and	NULL
incubated	NULL
for	NULL
4	NULL
hours	NULL
at	NULL
37°C	NULL
.	NULL

After	NULL
incubation	NULL
,	NULL
100	NULL
gL	NULL
supernatant	NULL
was	NULL
collected	NULL
and	NULL
counted	NULL
in	NULL
a	NULL
B-counter	NULL
.	NULL

Spontaneous	NULL
release	NULL
never	NULL
exceeded	NULL
14	NULL
%	NULL
.	NULL

For	NULL
blocking	NULL
experiments	NULL
,	NULL
various	NULL
concentrations	NULL
(	NULL
10	NULL
to	NULL
0.01	NULL
ug/mL	NULL
)	NULL
or	NULL
dilutions	NULL
of	NULL
MoAbs	NULL
directed	NULL
against	NULL
CD3	NULL
HLA	NULL
class	NULL
I	NULL
or	NULL
II	NULL
molecules	NULL
were	NULL
added	NULL
to	NULL
the	NULL
targets	NULL
before	NULL
mixing	NULL
targets	NULL
and	NULL
effector	NULL
cells	NULL
.	NULL

In	NULL
control	NULL
wells	NULL
,	NULL
irrelevant	NULL
mouse	NULL
Ig	NULL
was	NULL
added	NULL
.	NULL

RESULTS	NULL
Polyclonal	NULL
lines	NULL
.	NULL

A	NULL
specific	NULL
proliferation	NULL
to	NULL
peptide	NULL
BCR1/25	NULL
was	NULL
observed	NULL
in	NULL
4/5	NULL
donors	NULL
,	NULL
with	NULL
0.8	NULL
%	NULL
to	NULL
3	NULL
%	NULL
of	NULL
positive	NULL
wells	NULL
and	NULL
stimulation	NULL
indexes	NULL
(	NULL
stimulation	NULL
index	NULL
[	NULL
SI	NULL
]	NULL
,	NULL
counts	NULL
per	NULL
minute	NULL
test	NULL
well/counts	NULL
per	NULL
minute	NULL
control	NULL
well	NULL
)	NULL
ranging	NULL
from	NULL
2.1	NULL
to	NULL
16.1	NULL
.	NULL

These	NULL
polyclonal	NULL
lines	NULL
were	NULL
predominantly	NULL
CD4*	NULL
or	NULL
were	NULL
a	NULL
mixture	NULL
of	NULL
CD4	NULL
and	NULL
CD8-y/é	NULL
lymphocytes	NULL
.	NULL

No	NULL
line	NULL
showed	NULL
specific	NULL
cytotoxicity	NULL
against	NULL
peptide-pulsed	NULL
APC	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Proliferative	NULL
response	NULL
of	NULL
lymphocyte	NULL
clones	NULL
.	NULL

-	NULL
Five	NULL
lines	NULL
from	NULL
donor	NULL
DE	NULL
were	NULL
cloned	NULL
by	NULL
limiting	NULL
dilution	NULL
(	NULL
1	NULL
cell/well	NULL
)	NULL
.	NULL

The	NULL
probability	NULL
of	NULL
clonality	NULL
for	NULL
the	NULL
growing	NULL
wells	NULL
ranged	NULL
from	NULL
91	NULL
%	NULL
to	NULL
99.2	NULL
%	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
line	NULL
of	NULL
origin	NULL
and	NULL
the	NULL
relative	NULL
cloning	NULL
efficiency	NULL
.	NULL

Among	NULL
the	NULL
186	NULL
clones	NULL
obtained	NULL
,	NULL
59	NULL
showed	NULL
specific	NULL
proliferation	NULL
to	NULL
BCR1/25	NULL
in	NULL
a	NULL
first	NULL
experiment	NULL
(	NULL
SI	NULL
4.6-61	NULL
)	NULL
.	NULL

Fifty-one	NULL
clones	NULL
(	NULL
86	NULL
%	NULL
)	NULL
confirmed	NULL
this	NULL
specific	NULL
response	NULL
in	NULL
a	NULL
second	NULL
experiment	NULL
in	NULL
which	NULL
a	NULL
dose-response	NULL
curve	NULL
was	NULL
also	NULL
obtained	NULL
.	NULL

Twelve	NULL
clones	NULL
were	NULL
selected	NULL
for	NULL
further	NULL
analysis	NULL
.	NULL

All	NULL
clones	NULL
show	NULL
the	NULL
following	NULL
phenotype	NULL
:	NULL
CD3	NULL
#	NULL
,	NULL
CD4*	NULL
,	NULL
T-cell	NULL
Receptor	NULL
(	NULL
TCR	NULL
)	NULL
a/8*	NULL
,	NULL
CD87	NULL
,	NULL
TCR	NULL
7/87	NULL
.	NULL

Figure	NULL
1	NULL
shows	NULL
that	NULL
proliferation	NULL
occurred	NULL
in	NULL
all	NULL
six	NULL
representative	NULL
clones	NULL
at	NULL
peptide	NULL
concentrations	NULL
between	NULL
200	NULL
nmol/L	NULL
and	NULL
2	NULL
umol/L	NULL
.	NULL

Counts	NULL
per	NULL
minute	NULL
values	NULL
further	NULL
increased	NULL
at	NULL
higher	NULL
concentrations	NULL
and	NULL
reached	NULL
a	NULL
plateau	NULL
at	NULL
20	NULL
umol/L	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
this	NULL
response	NULL
was	NULL
analyzed	NULL
.	NULL

DE	NULL
clones	NULL
were	NULL
stimulated	NULL
with	NULL
XR-APC	NULL
pulsed	NULL
with	NULL
BCR1/25	NULL
or	NULL
peptides	NULL
corresponding	NULL
to	NULL
the	NULL
normal	NULL
pml	NULL
,	NULL
a	NULL
different	NULL
pml/RAR	NULL
«	NULL
fusion	NULL
peptide	NULL
(	NULL
BCR3	NULL
)	NULL
in	NULL
which	NULL
the	NULL
same	NULL
part	NULL
of	NULL
RARa	NULL
«	NULL
is	NULL
fused	NULL
to	NULL
a	NULL
different	NULL
part	NULL
of	NULL
pral	NULL
(	NULL
more	NULL
NH	NULL
terminal	NULL
than	NULL
in	NULL
the	NULL
beri	NULL
type	NULL
)	NULL
,	NULL
or	NULL
a	NULL
mutated	NULL
ras	NULL
peptide	NULL
.	NULL

The	NULL
results	NULL
of	NULL
a	NULL
representative	NULL
experiment	NULL
(	NULL
Fig	NULL
2	NULL
)	NULL
indicate	NULL
that	NULL
DE	NULL
clones	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IMMUNOGENICITY	NULL
OF	NULL
THE	NULL
pmI/RAR	NULL
«	NULL
FUSION	NULL
PROTEIN	NULL
CPM	NULL
(	NULL
x	NULL
103	NULL
)	NULL
0	NULL
20nM	NULL
PEPTIDE	NULL
CONCENTRATION	NULL
200nM	NULL
2M	NULL
Fig	NULL
1	NULL
.	NULL

-	NULL
Proliferative	NULL
response	NULL
of	NULL
six	NULL
DE	NULL
clones	NULL
to	NULL
peptide	NULL
BCR1/	NULL
25	NULL
.	NULL

DE	NULL
T-cell	NULL
clones	NULL
(	NULL
5	NULL
X	NULL
10*/well	NULL
)	NULL
were	NULL
cultured	NULL
for	NULL
48	NULL
hours	NULL
with	NULL
autologous	NULL
irradiated	NULL
(	NULL
800	NULL
cGy	NULL
,	NULL
XR	NULL
)	NULL
EBV-transformed	NULL
LCLs	NULL
(	NULL
105/	NULL
well	NULL
)	NULL
+	NULL
BCR1/25	NULL
,	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
18	NULL
hours	NULL
with	NULL
°HTdR	NULL
,	NULL
and	NULL
harvested	NULL
.	NULL

The	NULL
peptide	NULL
concentration	NULL
shown	NULL
refers	NULL
to	NULL
the	NULL
final	NULL
concentration	NULL
in	NULL
the	NULL
well	NULL
.	NULL

Counts	NULL
per	NULL
minute	NULL
values	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
replicates	NULL
.	NULL

SD	NULL
never	NULL
exceeded	NULL
15	NULL
%	NULL
of	NULL
the	NULL
mean	NULL
counts	NULL
per	NULL
minute	NULL
.	NULL

recognize	NULL
BCR	NULL
1/25	NULL
,	NULL
whereas	NULL
they	NULL
are	NULL
unable	NULL
to	NULL
react	NULL
to	NULL
peptides	NULL
corresponding	NULL
to	NULL
the	NULL
normal	NULL
pml	NULL
or	NULL
to	NULL
the	NULL
normal	NULL
RARa	NULL
(	NULL
peptide	NULL
BCR3	NULL
)	NULL
proteins	NULL
or	NULL
against	NULL
a	NULL
ras	NULL
peptide	NULL
previously	NULL
shown	NULL
to	NULL
be	NULL
immunogenic	NULL
in	NULL
vitro	NULL
.	NULL
'	NULL

''	NULL
No	NULL
response	NULL
was	NULL
also	NULL
observed	NULL
against	NULL
b3	NULL
,	NULL
a	NULL
19-mer	NULL
ber/abl	NULL
fusion	NULL
peptide	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
HLA	NULL
restriction	NULL
of	NULL
DE	NULL
clones	NULL
was	NULL
subsequently	NULL
investigated	NULL
by	NULL
blocking	NULL
experiments	NULL
using	NULL
MoAbs	NULL
against	NULL
CD3	NULL
,	NULL
HLA	NULL
class	NULL
I	NULL
and	NULL
II	NULL
molecules	NULL
.	NULL

Figure	NULL
3	NULL
shows	NULL
that	NULL
anti-CD3	NULL
or	NULL
-HLA	NULL
class	NULL
II	NULL
(	NULL
DR	NULL
)	NULL
molecule	NULL
MoAbs	NULL
significantly	NULL
inhibited	NULL
the	NULL
proliferative	NULL
response	NULL
to	NULL
BCR1/25	NULL
in	NULL
all	NULL
the	NULL
clones	NULL
tested	NULL
.	NULL

No	NULL
significant	NULL
inhibition	NULL
was	NULL
caused	NULL
by	NULL
these	NULL
MoAbs	NULL
at	NULL
the	NULL
concentrations	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
when	NULL
rIL-2	NULL
was	NULL
used	NULL
as	NULL
proliferative	NULL
stimulus	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
two	NULL
allogeneic	NULL
LCLs	NULL
to	NULL
present	NULL
BCR1/25	NULL
to	NULL
DE	NULL
clones	NULL
was	NULL
also	NULL
investigated	NULL
to	NULL
define	NULL
more	NULL
precisely	NULL
the	NULL
DR	NULL
restriction	NULL
molecule	NULL
involved	NULL
.	NULL

LE	NULL
cells	NULL
(	NULL
DR	NULL
1,3	NULL
)	NULL
,	NULL
sharing	NULL
no	NULL
DR	NULL
molecule	NULL
with	NULL
DE	NULL
(	NULL
DR	NULL
11	NULL
and	NULL
13	NULL
)	NULL
,	NULL
failed	NULL
to	NULL
present	NULL
BCR	NULL
1/25	NULL
.	NULL

Cells	NULL
from	NULL
donor	NULL
VG	NULL
(	NULL
DR	NULL
11	NULL
and	NULL
7	NULL
)	NULL
,	NULL
who	NULL
shared	NULL
DR	NULL
11	NULL
with	NULL
DE	NULL
,	NULL
induced	NULL
proliferation	NULL
of	NULL
DE	NULL
clones	NULL
when	NULL
pulsed	NULL
with	NULL
BCR1/25	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
the	NULL
involvement	NULL
of	NULL
HLA-DR	NULL
11	NULL
in	NULL
the	NULL
response	NULL
of	NULL
DE	NULL
T	NULL
clones	NULL
to	NULL
BCR	NULL
1/25	NULL
.	NULL

This	NULL
hypothesis	NULL
was	NULL
tested	NULL
using	NULL
murine	NULL
fibroblasts	NULL
transfected	NULL
with	NULL
HLA-DR	NULL
genes	NULL
and	NULL
known	NULL
to	NULL
express	NULL
their	NULL
encoded	NULL
molecules	NULL
.	NULL

``	NULL
!	NULL

Figure	NULL
4	NULL
shows	NULL
that	NULL
line	NULL
L91.7	NULL
(	NULL
DR	NULL
11	NULL
transfectant	NULL
)	NULL
was	NULL
able	NULL
to	NULL
present	NULL
BCR	NULL
1/25	NULL
to	NULL
clones	NULL
C6	NULL
,	NULL
G2	NULL
,	NULL
and	NULL
G10	NULL
,	NULL
whereas	NULL
lines	NULL
R	NULL
3.2.1	NULL
(	NULL
DR4	NULL
transfectant	NULL
)	NULL
and	NULL
L182	NULL
.	NULL

1	NULL
(	NULL
DR	NULL
14	NULL
transfectant	NULL
)	NULL
failed	NULL
to	NULL
stimulate	NULL
DE	NULL
clones	NULL
.	NULL

No	NULL
HLA-DR	NULL
13	NULL
transfectant	NULL
was	NULL
available	NULL
to	NULL
us	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
DR11	NULL
is	NULL
the	NULL
dominant	NULL
restriction	NULL
element	NULL
for	NULL
at	NULL
least	NULL
clones	NULL
C6	NULL
,	NULL
G2	NULL
,	NULL
and	NULL
G10	NULL
.	NULL

1371	NULL
go	NULL
-	NULL
pe.Ccé	NULL
so	NULL
-	NULL
DE.F2	NULL
~	NULL
in	NULL
7	NULL
®	NULL
2	NULL
407	NULL
40	NULL
e	NULL
?	NULL

$	NULL
3	NULL
-	NULL
O	NULL
.	NULL

9	NULL
207	NULL
20	NULL
o	NULL
0	NULL
se	NULL
--	NULL
C-1~	NULL
J-	NULL
[	NULL
9	NULL
102	NULL
3	NULL
4	NULL
50	NULL
60	NULL
7	NULL
102	NULL
3	NULL
4	NULL
50	NULL
6	NULL
7	NULL
120	NULL
-	NULL
DE	NULL
.	NULL

G5	NULL
120	NULL
-	NULL
DE	NULL
.	NULL

G10	NULL
3	NULL
-	NULL
]	NULL
2	NULL
~	NULL
so	NULL
-	NULL
so	NULL
p3	NULL
~	NULL
a	NULL
.	NULL

9	NULL
40	NULL
-	NULL
40	NULL
7	NULL
o	NULL
o	NULL
3	NULL
102	NULL
3	NULL
4	NULL
5	NULL
60	NULL
7	NULL
102	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
1	NULL
:	NULL
Lymphocytes	NULL
alone	NULL
5	NULL
:	NULL
Lymphocytes	NULL
+	NULL
peptide	NULL
pm	NULL
]	NULL
+	NULL
APC	NULL
2	NULL
:	NULL
Lymphocytes	NULL
+	NULL
peptide	NULL
borl/25	NULL
6	NULL
:	NULL
Lymphocytes	NULL
+	NULL
peptide	NULL
berl/25+	NULL
APC	NULL
3	NULL
:	NULL
Lymphocytes	NULL
*	NULL
peptide	NULL
bor3	NULL
+	NULL
APC	NULL
7	NULL
:	NULL
Lymphocytes	NULL
+	NULL
APC	NULL
L	NULL
:	NULL
Lymphocytes	NULL
+	NULL
peptide	NULL
ras	NULL
+	NULL
APC	NULL
Fig	NULL
2	NULL
.	NULL

-	NULL
Proliferative	NULL
response	NULL
of	NULL
four	NULL
DE	NULL
clones	NULL
to	NULL
BCR1/25	NULL
or	NULL
to	NULL
control	NULL
peptides	NULL
.	NULL

Each	NULL
peptide	NULL
was	NULL
used	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
2	NULL
The	NULL
culture	NULL
conditions	NULL
were	NULL
the	NULL
same	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
1	NULL
.	NULL

SD	NULL
<	NULL
10	NULL
%	NULL
of	NULL
the	NULL
mean	NULL
counts	NULL
per	NULL
minute	NULL
.	NULL

T-cell	NULL
clones	NULL
were	NULL
also	NULL
grown	NULL
from	NULL
donor	NULL
LE	NULL
.	NULL

Among	NULL
343	NULL
growing	NULL
clones	NULL
,	NULL
186	NULL
showed	NULL
specific	NULL
response	NULL
to	NULL
BCR1/25	NULL
,	NULL
with	NULL
SI	NULL
similar	NULL
to	NULL
donor	NULL
DE	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
clones	NULL
were	NULL
not	NULL
further	NULL
studied	NULL
.	NULL

16	NULL
DE	NULL
.	NULL

C6	NULL
DE	NULL
.	NULL

F2	NULL
DE	NULL
.	NULL

G2	NULL
12	NULL
-	NULL
&	NULL
8	NULL
3	NULL
a	NULL
.	NULL

-	NULL
-	NULL
]	NULL
U	NULL
4	NULL
4	NULL
o	NULL
10	NULL
2	NULL
3	NULL
4	NULL
10	NULL
2	NULL
3	NULL
4	NULL
10	NULL
2	NULL
3	NULL
4	NULL
1	NULL
=	NULL
Lymphocytes	NULL
+	NULL
peptide	NULL
bor1/25	NULL
+APC	NULL
2	NULL
=	NULL
Lymphocytes	NULL
+	NULL
peptide	NULL
berl/25	NULL
+APC	NULL
+	NULL
anti	NULL
CD3	NULL
1	NULL
pg/ml	NULL
3	NULL
=	NULL
Lymphocytes	NULL
+	NULL
peptideber1/25	NULL
+APC	NULL
+	NULL
anti	NULL
HLA	NULL
DR	NULL
1/200	NULL
4	NULL
=	NULL
Lymphocytes	NULL
+	NULL
peptideber1/25	NULL
+APC	NULL
+	NULL
anti	NULL
HLA	NULL
clI	NULL
1/100	NULL
Fig	NULL
3	NULL
.	NULL

-	NULL
Effect	NULL
of	NULL
MoAbs	NULL
directed	NULL
against	NULL
CD3	NULL
or	NULL
HLA	NULL
class	NULL
|	NULL
or	NULL
II	NULL
molecules	NULL
on	NULL
the	NULL
proliferative	NULL
response	NULL
of	NULL
three	NULL
DE	NULL
clones	NULL
to	NULL
BCR1/	NULL
25	NULL
.	NULL

Experimental	NULL
conditions	NULL
were	NULL
the	NULL
same	NULL
described	NULL
in	NULL
Fig	NULL
2	NULL
,	NULL
with	NULL
the	NULL
exception	NULL
that	NULL
4	NULL
X	NULL
10°	NULL
lymphocytes/well	NULL
were	NULL
used	NULL
and	NULL
that	NULL
the	NULL
counts	NULL
per	NULL
minute	NULL
of	NULL
XR-LCL	NULL
(	NULL
4,773	NULL
cpm	NULL
)	NULL
were	NULL
subtracted	NULL
from	NULL
the	NULL
total	NULL
counts	NULL
per	NULL
minute	NULL
values	NULL
.	NULL

MoAbs	NULL
were	NULL
added	NULL
into	NULL
the	NULL
wells	NULL
containing	NULL
the	NULL
XR-LCL	NULL
cells	NULL
immediately	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
DE	NULL
clones	NULL
.	NULL

Anti-CD3	NULL
was	NULL
used	NULL
as	NULL
a	NULL
purified	NULL
antibody	NULL
,	NULL
whereas	NULL
anti-HLA	NULL
class	NULL
I	NULL
(	NULL
W6/32	NULL
,	NULL
from	NULL
ATCC	NULL
)	NULL
or	NULL
II	NULL
MoAbs	NULL
were	NULL
in	NULL
the	NULL
form	NULL
of	NULL
diluted	NULL
ascites	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1372	NULL
A	NULL
pe	NULL
cs	NULL
40000	NULL
-	NULL
_	NULL
30000	NULL
7	NULL
U	NULL
a	NULL
>	NULL
a.	NULL
L6	NULL
]	NULL
20000	NULL
-	NULL
_	NULL
10000	NULL
o	NULL
wm	NULL
%	NULL
[	NULL
2A	NULL
5	NULL
6	NULL
7	NULL
COLUMN	NULL
NUMBER	NULL
De	NULL
G10	NULL
C2	NULL
i	NULL
T	NULL
T	NULL
I	NULL
T	NULL
T	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
COLUMN	NULL
NUMBER	NULL
Cytotoxic	NULL
activity	NULL
of	NULL
DE	NULL
clones	NULL
.	NULL

-	NULL
DE	NULL
T-cell	NULL
clones	NULL
were	NULL
also	NULL
analyzed	NULL
for	NULL
cytotoxicity	NULL
against	NULL
autologous	NULL
LCL	NULL
s	NULL
pulsed	NULL
with	NULL
BCR1/25	NULL
.	NULL

All	NULL
but	NULL
1	NULL
of	NULL
the	NULL
12	NULL
clones	NULL
tested	NULL
showed	NULL
no	NULL
cytotoxic	NULL
activity	NULL
.	NULL

Clone	NULL
GS	NULL
exerted	NULL
a	NULL
high	NULL
and	NULL
specific	NULL
lysis	NULL
of	NULL
peptide-pulsed	NULL
autologous	NULL
LCLs	NULL
(	NULL
Fig	NULL
5	NULL
)	NULL
.	NULL

DE	NULL
LCLs	NULL
pulsed	NULL
with	NULL
BCR3	NULL
or	NULL
with	NULL
peptide	NULL
pml	NULL
were	NULL
not	NULL
lysed	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Anti-CD3	NULL
and	NULL
-DR	NULL
MoAbs	NULL
induced	NULL
a	NULL
significant	NULL
and	NULL
dose-dependent	NULL
inhibition	NULL
of	NULL
cytotoxicity	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Anti-HLA	NULL
class	NULL
I	NULL
MoAbs	NULL
did	NULL
not	NULL
seem	NULL
to	NULL
exert	NULL
any	NULL
significant	NULL
inhibition	NULL
of	NULL
cytotoxicity	NULL
.	NULL

Although	NULL
clone	NULL
GS	NULL
showed	NULL
the	NULL
same	NULL
pattern	NULL
of	NULL
proliferation	NULL
to	NULL
pml/RARa	NULL
peptides	NULL
as	NULL
the	NULL
other	NULL
DE	NULL
clones	NULL
tested	NULL
,	NULL
the	NULL
recognition	NULL
of	NULL
a	NULL
different	NULL
epitope	NULL
during	NULL
the	NULL
cytotoxicity	NULL
assay	NULL
can	NULL
not	NULL
be	NULL
excluded	NULL
.	NULL

Induction	NULL
of	NULL
proliferation	NULL
of	NULL
DE	NULL
clones	NULL
by	NULL
DE	NULL
LCL	NULL
expressing	NULL
the	NULL
pml/RARa	NULL
fusion	NULL
protein	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
the	NULL
intracellular	NULL
processing	NULL
of	NULL
the	NULL
pmI/RARa	NULL
protein	NULL
GAMBACORTI-PASSERINI	NULL
ET	NULL
AL	NULL
850000	NULL
40000	NULL
DE	NULL
G2	NULL
30000	NULL
CPM	NULL
20000	NULL
7	NULL
10000	NULL
COLUMN	NULL
NUMBER	NULL
Fig	NULL
4	NULL
.	NULL

-	NULL
Ability	NULL
of	NULL
different	NULL
DR	NULL
transfectants	NULL
to	NULL
present	NULL
BCR1/25	NULL
to	NULL
DE	NULL
T-cell	NULL
clones	NULL
C6	NULL
(	NULL
A	NULL
)	NULL
,	NULL
G2	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
G10	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Murine	NULL
fibroblasts	NULL
transfected	NULL
with	NULL
HLA-DR11	NULL
(	NULL
L.91.7	NULL
)	NULL
,	NULL
-DR4	NULL
(	NULL
R/3.2.1	NULL
)	NULL
,	NULL
and	NULL
-DR14	NULL
{	NULL
(	NULL
L182.1	NULL
)	NULL
were	NULL
pulsed	NULL
with	NULL
BCR1/25	NULL
(	NULL
2	NULL
umol/L	NULL
final	NULL
concentration	NULL
}	NULL
,	NULL
irradiated	NULL
(	NULL
400	NULL
cGy	NULL
)	NULL
,	NULL
and	NULL
added	NULL
to	NULL
96-well	NULL
plates	NULL
(	NULL
5	NULL
x	NULL
10*/weill	NULL
}	NULL
.	NULL

Autologous	NULL
XR	NULL
(	NULL
800	NULL
cGy	NULL
)	NULL
LCL	NULL
were	NULL
used	NULL
at	NULL
10°	NULL
cells/well	NULL
.	NULL

Lymphocytes	NULL
were	NULL
added	NULL
at	NULL
5	NULL
X	NULL
10*/well	NULL
,	NULL
cultured	NULL
for	NULL
48	NULL
hours	NULL
,	NULL
pulsed	NULL
with	NULL
°HTdR	NULL
for	NULL
an	NULL
additional	NULL
18	NULL
hours	NULL
,	NULL
harvested	NULL
,	NULL
and	NULL
counted	NULL
.	NULL

The	NULL
values	NULL
are	NULL
expressed	NULL
as	NULL
counts	NULL
per	NULL
minute	NULL
.	NULL

SD	NULL
were	NULL
<	NULL
10	NULL
%	NULL
of	NULL
the	NULL
mean	NULL
counts	NULL
per	NULL
minute	NULL
.	NULL

Column	NULL
1	NULL
,	NULL
lymphocytes	NULL
(	NULL
ly	NULL
)	NULL
+	NULL
LCL	NULL
;	NULL
column	NULL
2	NULL
,	NULL
ly	NULL
+	NULL
LCL	NULL
+	NULL
BCR1/25	NULL
;	NULL
column	NULL
3	NULL
,	NULL
ly	NULL
+	NULL
line	NULL
91.7	NULL
;	NULL
column	NULL
4	NULL
,	NULL
ly	NULL
+	NULL
line	NULL
91.7	NULL
+	NULL
BCR1/25	NULL
;	NULL
column	NULL
5	NULL
,	NULL
ly	NULL
+	NULL
line	NULL
R/3.2.1	NULL
+	NULL
BCR1/25	NULL
;	NULL
column	NULL
6	NULL
,	NULL
ly	NULL
+	NULL
line	NULL
L182.1	NULL
+	NULL
BCR1/25	NULL
;	NULL
column	NULL
7	NULL
,	NULL
ly	NULL
alone	NULL
.	NULL

XR-fibroblasts	NULL
incorporated	NULL
297	NULL
to	NULL
1,140	NULL
cpm	NULL
;	NULL
XR-LCL	NULL
incorporated	NULL
2,380	NULL
+	NULL
60	NULL
(	NULL
SD	NULL
)	NULL
cpm	NULL
.	NULL

can	NULL
produce	NULL
peptides	NULL
recognizable	NULL
by	NULL
the	NULL
BCR	NULL
1/25-induced	NULL
DE	NULL
clones	NULL
,	NULL
DE	NULL
LCL	NULL
were	NULL
infected	NULL
with	NULL
a	NULL
retroviral	NULL
vector	NULL
containing	NULL
the	NULL
ber1	NULL
type	NULL
of	NULL
the	NULL
pmi/RARa	NULL
fusion	NULL
gene	NULL
.	NULL

The	NULL
resulting	NULL
line	NULL
(	NULL
named	NULL
DE/PR	NULL
)	NULL
expresses	NULL
a	NULL
protein	NULL
with	NULL
an	NULL
apparent	NULL
molecular	NULL
weight	NULL
(	NULL
Mr	NULL
)	NULL
of	NULL
$	NULL
5	NULL
Kd	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
expected	NULL
Mr	NULL
calculated	NULL
from	NULL
the	NULL
DNA	NULL
sequence	NULL
(	NULL
Fig	NULL
6	NULL
)	NULL
.	NULL

The	NULL
stimulatory	NULL
activity	NULL
of	NULL
the	NULL
DE/PR	NULL
cell	NULL
line	NULL
on	NULL
four	NULL
DE	NULL
T-cell	NULL
clones	NULL
was	NULL
tested	NULL
in	NULL
two	NULL
consecutive	NULL
experiments	NULL
.	NULL

Table	NULL
2	NULL
presents	NULL
the	NULL
results	NULL
obtained	NULL
in	NULL
two	NULL
representative	NULL
clones	NULL
(	NULL
the	NULL
remaining	NULL
two	NULL
clones	NULL
gave	NULL
similar	NULL
results	NULL
in	NULL
2/2	NULL
exper-iments	NULL
)	NULL
.	NULL

The	NULL
DE/PR	NULL
cell	NULL
line	NULL
was	NULL
able	NULL
to	NULL
induce	NULL
the	NULL
proliferation	NULL
of	NULL
the	NULL
DE	NULL
clones	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
.	NULL

The	NULL
stimulatory	NULL
activity	NULL
of	NULL
the	NULL
DE/PR	NULL
line	NULL
was	NULL
inhibited	NULL
by	NULL
the	NULL
blocking	NULL
of	NULL
the	NULL
HLA-DR	NULL
molecules	NULL
;	NULL
blocking	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
was	NULL
ineffective	NULL
.	NULL

DE/PR	NULL
cells	NULL
were	NULL
able	NULL
to	NULL
induce	NULL
a	NULL
level	NULL
of	NULL
proliferation	NULL
of	NULL
DE	NULL
clones	NULL
lower	NULL
than	NULL
that	NULL
obtained	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IMMUNOGENICITY	NULL
OF	NULL
THE	NULL
pmI/RAR	NULL
«	NULL
FUSION	NULL
PROTEIN	NULL
60	NULL
-	NULL
DE.G5s	NULL
50	NULL
|	NULL
w	NULL
(	NULL
Vp	NULL
)	NULL
2	NULL
U	NULL
w	NULL
&	NULL
QA	NULL
25	NULL
[	NULL
~	NULL
M	NULL
0M	NULL
20	NULL
10	NULL
5	NULL
2.5	NULL
E/T	NULL
RaAtiO	NULL
Fig	NULL
5	NULL
.	NULL

Cytotoxic	NULL
activity	NULL
of	NULL
clone	NULL
DEGS	NULL
against	NULL
DE	NULL
LCL	NULL
cells	NULL
pulsed	NULL
with	NULL
peptide	NULL
BCR1/25	NULL
:	NULL
A	NULL
,	NULL
autologous	NULL
LCL	NULL
;	NULL
a	NULL
,	NULL
autologous	NULL
LCL	NULL
pulsed	NULL
with	NULL
BCR1/25	NULL
.	NULL

with	NULL
the	NULL
usual	NULL
concentrations	NULL
of	NULL
BCR1/25	NULL
used	NULL
,	NULL
and	NULL
comparable	NULL
to	NULL
1	NULL
to	NULL
2	NULL
ug/ml	NULL
of	NULL
BCR1/25	NULL
.	NULL

No	NULL
significant	NULL
proliferation	NULL
of	NULL
DE	NULL
clones	NULL
was	NULL
observed	NULL
after	NULL
coculture	NULL
with	NULL
the	NULL
control	NULL
DE/SN	NULL
cell	NULL
line	NULL
.	NULL

DISCUSSION	NULL
The	NULL
present	NULL
data	NULL
indicate	NULL
that	NULL
a	NULL
peptide	NULL
corresponding	NULL
to	NULL
the	NULL
fusion	NULL
region	NULL
of	NULL
the	NULL
pmIl/RARa	NULL
protein	NULL
present	NULL
in	NULL
APL	NULL
Table	NULL
1	NULL
.	NULL

Effect	NULL
of	NULL
MoAbs	NULL
Directed	NULL
Against	NULL
the	NULL
TCR	NULL
,	NULL
HLA	NULL
Class	NULL
I	NULL
and	NULL
II	NULL
Molecules	NULL
on	NULL
the	NULL
Cytotoxic	NULL
Activity	NULL
of	NULL
Clone	NULL
DE	NULL
G5	NULL
on	NULL
DE	NULL
LCL	NULL
Cells	NULL
Pulsed	NULL
With	NULL
BCR1/25	NULL
MoAb	NULL
Used	NULL
Concentration/Dilution	NULL
%	NULL
Specific	NULL
Lysis	NULL
None	NULL
--	NULL
52	NULL
Anti-CD3	NULL
10	NULL
ug/ml	NULL
3	NULL
1	NULL
ug/ml	NULL
2	NULL
.1	NULL
ug/ml	NULL
15	NULL
.01	NULL
ug/ml	NULL
35	NULL
Anti-HLA	NULL
class	NULL
I	NULL
1/50	NULL
42	NULL
Anti-HLA	NULL
class	NULL
II	NULL
1/50	NULL
20	NULL
1/100	NULL
42	NULL
1/1,000	NULL
55	NULL
Four-hour	NULL
*'Cr	NULL
release	NULL
assay	NULL
,	NULL
E/T	NULL
ratio	NULL
=	NULL
5/1	NULL
.	NULL

The	NULL
antibodies	NULL
were	NULL
dispensed	NULL
into	NULL
the	NULL
wells	NULL
containing	NULL
the	NULL
target	NULL
cells	NULL
before	NULL
the	NULL
effectors	NULL
were	NULL
added	NULL
.	NULL

SR	NULL
was	NULL
9.7	NULL
%	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
MoAbs	NULL
did	NULL
not	NULL
change	NULL
the	NULL
SR.	NULL
1373	NULL
kd	NULL
116.2	NULL
97.4	NULL
«	NULL
mmirg	NULL
)	NULL
-PML-RARa	NULL
66.2	NULL
esing	NULL
-	NULL
RARa	NULL
426	NULL
-	NULL
0	NULL
<	NULL
=	NULL
>	NULL
~	NULL
31	NULL
Fig	NULL
6	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
pml/RAR	NULL
«	NULL
protein	NULL
expression	NULL
in	NULL
infected	NULL
DE	NULL
LCL	NULL
.	NULL

C	NULL
denotes	NULL
DE/SN	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
control	NULL
vector	NULL
LXSN	NULL
;	NULL
MR	NULL
denotes	NULL
DE/PR	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
LSPRSN	NULL
vector	NULL
.	NULL

The	NULL
electrophoretic	NULL
migration	NULL
of	NULL
molecular	NULL
weight	NULL
standards	NULL
is	NULL
indicated	NULL
on	NULL
the	NULL
left	NULL
.	NULL

cells	NULL
can	NULL
be	NULL
specifically	NULL
recognized	NULL
by	NULL
human	NULL
CD4	NULL
lymphocytes	NULL
.	NULL

The	NULL
recognition	NULL
seems	NULL
to	NULL
be	NULL
restricted	NULL
by	NULL
HLA-DR	NULL
I1	NULL
1	NULL
in	NULL
the	NULL
donor	NULL
studied	NULL
.	NULL

To	NULL
our	NULL
knowledge	NULL
,	NULL
this	NULL
represents	NULL
the	NULL
first	NULL
evidence	NULL
that	NULL
pml/RARa	NULL
«	NULL
fusion	NULL
proteins	NULL
can	NULL
be	NULL
specif-	NULL
Table	NULL
2	NULL
.	NULL

Ability	NULL
of	NULL
DE/PR	NULL
LCL	NULL
Cells	NULL
,	NULL
Expressing	NULL
the	NULL
pml/RAR	NULL
«	NULL
BCR1	NULL
Type	NULL
Protein	NULL
,	NULL
to	NULL
Induce	NULL
Proliferation	NULL
of	NULL
DE	NULL
Clones	NULL
C7	NULL
and	NULL
F2	NULL
T-Cell	NULL
Clone	NULL
Stimulus	NULL
DE	NULL
F2	NULL
DE	NULL
C7	NULL
None	NULL
230	NULL
481	NULL
XR	NULL
DE	NULL
LCL	NULL
5,523	NULL
6,438	NULL
XR	NULL
DE	NULL
LCL	NULL
+	NULL
BCR1/25	NULL
20	NULL
umol/L	NULL
125,640	NULL
214,813	NULL
XR	NULL
DE	NULL
LCL	NULL
+	NULL
BCR1/25	NULL
2	NULL
umol/L	NULL
89,097	NULL
175,063	NULL
XR	NULL
DE	NULL
LCL	NULL
+	NULL
BCR1/25	NULL
.2	NULL
umol/L	NULL
35,414	NULL
59,876	NULL
XR	NULL
DE/SN	NULL
LCL	NULL
2,798	NULL
3,012	NULL
XR	NULL
DE/PR	NULL
LCL	NULL
(	NULL
10°	NULL
cells/well	NULL
)	NULL
64,780	NULL
134,143	NULL
XR	NULL
DE/PR	NULL
LCL	NULL
(	NULL
3.5	NULL
x	NULL
10°	NULL
cells/well	NULL
)	NULL
30,297	NULL
53,723	NULL
XR	NULL
DE/PR	NULL
LCL	NULL
(	NULL
10*	NULL
cells/well	NULL
)	NULL
8,057	NULL
13,152	NULL
XR	NULL
DE/PR	NULL
LCL	NULL
(	NULL
10°	NULL
cells/well	NULL
)	NULL
+	NULL
anti-HLA	NULL
class	NULL
I	NULL
(	NULL
1/100	NULL
)	NULL
66,828	NULL
126,380	NULL
XR	NULL
DE/PR	NULL
LCL	NULL
(	NULL
10°	NULL
cells/well	NULL
)	NULL
+	NULL
anti-HLA	NULL
DR	NULL
(	NULL
1/200	NULL
)	NULL
6,209	NULL
11,493	NULL
DE	NULL
T-cell	NULL
clones	NULL
(	NULL
10°/well	NULL
)	NULL
were	NULL
cultured	NULL
for	NULL
2	NULL
days	NULL
with	NULL
the	NULL
indicated	NULL
stimulus	NULL
,	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
18	NULL
hours	NULL
with	NULL
°HTdR	NULL
,	NULL
and	NULL
harvested	NULL
.	NULL

Results	NULL
are	NULL
presented	NULL
as	NULL
counts	NULL
per	NULL
minute	NULL
and	NULL
represent	NULL
the	NULL
mean	NULL
of	NULL
three	NULL
replicates	NULL
.	NULL

SD	NULL
were	NULL
=10	NULL
%	NULL
of	NULL
the	NULL
mean	NULL
counts	NULL
per	NULL
minute	NULL
.	NULL

XR	NULL
LCL	NULL
(	NULL
10/well	NULL
)	NULL
uptake	NULL
ranged	NULL
from	NULL
1,050	NULL
to	NULL
5,356	NULL
cpm	NULL
.	NULL

The	NULL
DE/SN	NULL
LCL	NULL
represents	NULL
the	NULL
control	NULL
LCL	NULL
infected	NULL
with	NULL
an	NULL
empty	NULL
vector	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

1374	NULL
ically	NULL
recognized	NULL
by	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

The	NULL
absence	NULL
of	NULL
reactivity	NULL
toward	NULL
peptides	NULL
corresponding	NULL
to	NULL
the	NULL
same	NULL
regions	NULL
of	NULL
the	NULL
normal	NULL
pml	NULL
and	NULL
RARa	NULL
proteins	NULL
rules	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
these	NULL
clones	NULL
are	NULL
just	NULL
recognizing	NULL
a	NULL
portion	NULL
of	NULL
a	NULL
normal	NULL
protein	NULL
;	NULL
instead	NULL
it	NULL
shows	NULL
that	NULL
the	NULL
fusion	NULL
process	NULL
itself	NULL
is	NULL
generating	NULL
this	NULL
specificity	NULL
.	NULL

Experiments	NULL
performed	NULL
with	NULL
the	NULL
DE/	NULL
PR	NULL
cell	NULL
line	NULL
expressing	NULL
the	NULL
pml/RARa	NULL
«	NULL
hybrid	NULL
protein	NULL
show	NULL
that	NULL
peptide	NULL
BCR	NULL
1/25	NULL
or	NULL
a	NULL
cross-reacting	NULL
peptide	NULL
is	NULL
produced	NULL
during	NULL
the	NULL
intracellular	NULL
processing	NULL
of	NULL
the	NULL
pmi/RARa	NULL
«	NULL
protein	NULL
in	NULL
the	NULL
DE/PR	NULL
LCL	NULL
cells	NULL
.	NULL

Although	NULL
intracellular	NULL
proteins	NULL
are	NULL
believed	NULL
to	NULL
be	NULL
mainly	NULL
presented	NULL
by	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
,	NULL
``	NULL
they	NULL
can	NULL
also	NULL
be	NULL
presented	NULL
by	NULL
HLA	NULL
class	NULL
II	NULL
molecules	NULL
,	NULL
``	NULL
as	NULL
exemplified	NULL
in	NULL
our	NULL
experiments	NULL
.	NULL

However	NULL
,	NULL
the	NULL
possible	NULL
release	NULL
of	NULL
pml|/RARa	NULL
protein	NULL
in	NULL
the	NULL
cell	NULL
culture	NULL
medium	NULL
,	NULL
with	NULL
the	NULL
subsequent	NULL
uptake	NULL
and	NULL
intracellular	NULL
processing	NULL
and	NULL
presentation	NULL
of	NULL
the	NULL
endocytosed	NULL
protein	NULL
associated	NULL
with	NULL
HLA	NULL
class	NULL
II	NULL
molecules	NULL
can	NULL
not	NULL
be	NULL
excluded	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
peptide	NULL
BCR1/25	NULL
necessary	NULL
to	NULL
induce	NULL
the	NULL
proliferation	NULL
of	NULL
lymphocytes	NULL
is	NULL
higher	NULL
than	NULL
that	NULL
required	NULL
in	NULL
other	NULL
experimental	NULL
systems	NULL
.	NULL
``	NULL

This	NULL
can	NULL
be	NULL
caused	NULL
by	NULL
the	NULL
different	NULL
strength	NULL
of	NULL
the	NULL
antigen	NULL
or	NULL
by	NULL
the	NULL
low	NULL
affinity	NULL
of	NULL
in	NULL
vitro-activated	NULL
lympho-cytes	NULL
.	NULL
``	NULL

APL	NULL
cells	NULL
are	NULL
sensitive	NULL
to	NULL
cytotoxic	NULL
drugs	NULL
and	NULL
to	NULL
the	NULL
differentiating	NULL
action	NULL
of	NULL
retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
.	NULL

However	NULL
,	NULL
less	NULL
than	NULL
50	NULL
%	NULL
of	NULL
APL	NULL
patients	NULL
are	NULL
cured	NULL
by	NULL
standard	NULL
treatment	NULL
and	NULL
RA-induced	NULL
remissions	NULL
seem	NULL
to	NULL
be	NULL
short-lived	NULL
.	NULL
``	NULL

Therefore	NULL
,	NULL
new	NULL
treatment	NULL
modalities	NULL
are	NULL
needed	NULL
in	NULL
this	NULL
disease	NULL
.	NULL

The	NULL
use	NULL
of	NULL
pml/RARa	NULL
«	NULL
and	NULL
other	NULL
fusion	NULL
proteins	NULL
as	NULL
targets	NULL
for	NULL
specific	NULL
immunotherapy	NULL
is	NULL
attractive	NULL
for	NULL
two	NULL
main	NULL
reasons	NULL
:	NULL
(	NULL
1	NULL
)	NULL
these	NULL
proteins	NULL
are	NULL
selectively	NULL
expressed	NULL
in	NULL
neoplastic	NULL
cells	NULL
and	NULL
,	NULL
therefore	NULL
,	NULL
their	NULL
use	NULL
as	NULL
immunogens	NULL
should	NULL
not	NULL
induce	NULL
autoimmunity	NULL
;	NULL
(	NULL
2	NULL
)	NULL
the	NULL
pml/RARa	NULL
«	NULL
fusion	NULL
proteins	NULL
are	NULL
linked	NULL
to	NULL
the	NULL
process	NULL
of	NULL
malignant	NULL
transformation	NULL
;	NULL
therefore	NULL
the	NULL
selection	NULL
of	NULL
antigen-negative	NULL
leukemic	NULL
cells	NULL
should	NULL
not	NULL
constitute	NULL
a	NULL
major	NULL
problem	NULL
.	NULL

The	NULL
number	NULL
of	NULL
human	NULL
molecules	NULL
that	NULL
can	NULL
function	NULL
as	NULL
specific	NULL
tumor	NULL
antigen	NULL
is	NULL
now	NULL
expanding	NULL
.	NULL

Jung	NULL
et	NULL
al	NULL
showed	NULL
that	NULL
peptides	NULL
from	NULL
the	NULL
mutated	NULL
ras	NULL
protein	NULL
can	NULL
be	NULL
specifically	NULL
recognized	NULL
in	NULL
vitro	NULL
by	NULL
donor	NULL
T	NULL
lymphocytes	NULL
.	NULL

``	NULL
!	NULL

Van	NULL
der	NULL
Bruggen	NULL
et	NULL
al	NULL
identified	NULL
a	NULL
set	NULL
of	NULL
human	NULL
genes	NULL
that	NULL
code	NULL
for	NULL
molecules	NULL
recognized	NULL
by	NULL
human	NULL
antimelanoma	NULL
T-cell	NULL
clones	NULL
.	NULL
``	NULL

More	NULL
recently	NULL
,	NULL
Chen	NULL
et	NULL
al	NULL
showed	NULL
that	NULL
peptides	NULL
from	NULL
the	NULL
ber/abl	NULL
protein	NULL
,	NULL
when	NULL
injected	NULL
in	NULL
mice	NULL
,	NULL
can	NULL
induce	NULL
a	NULL
specific	NULL
T-cell	NULL
response	NULL
.	NULL
``	NULL

Many	NULL
aspects	NULL
need	NULL
to	NULL
be	NULL
investigated	NULL
further	NULL
and	NULL
dissected	NULL
before	NULL
the	NULL
clinical	NULL
use	NULL
of	NULL
these	NULL
peptides	NULL
can	NULL
be	NULL
considered	NULL
for	NULL
human	NULL
immunotherapy	NULL
,	NULL
whose	NULL
results	NULL
are	NULL
still	NULL
unsatis-factory	NULL
.	NULL

``	NULL
*	NULL
``	NULL
In	NULL
our	NULL
case	NULL
,	NULL
we	NULL
do	NULL
not	NULL
know	NULL
whether	NULL
this	NULL
response	NULL
can	NULL
be	NULL
obtained	NULL
with	NULL
lymphocytes	NULL
from	NULL
APL	NULL
patients	NULL
,	NULL
or	NULL
whether	NULL
a	NULL
similar	NULL
peptide	NULL
is	NULL
naturally	NULL
produced	NULL
in	NULL
vivo	NULL
by	NULL
APL	NULL
cells	NULL
.	NULL

Although	NULL
we	NULL
showed	NULL
that	NULL
the	NULL
pml/RARa	NULL
«	NULL
fusion	NULL
protein	NULL
could	NULL
induce	NULL
a	NULL
class	NULL
II-mediated	NULL
immune	NULL
response	NULL
,	NULL
we	NULL
ignore	NULL
whether	NULL
class	NULL
-associated	NULL
pml/RARa	NULL
«	NULL
peptides	NULL
can	NULL
be	NULL
produced	NULL
and	NULL
mediate	NULL
cellular	NULL
cytotoxicity	NULL
against	NULL
APL	NULL
cells	NULL
.	NULL

Some	NULL
of	NULL
these	NULL
issues	NULL
are	NULL
presently	NULL
being	NULL
investigated	NULL
in	NULL
our	NULL
laboratory	NULL
.	NULL

However	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
a	NULL
tumor-specific	NULL
molecule	NULL
closely	NULL
involved	NULL
in	NULL
the	NULL
process	NULL
of	NULL
leukemogenesis	NULL
can	NULL
be	NULL
specifically	NULL
recognized	NULL
by	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

GAMBACORTI-PASSERINI	NULL
ET	NULL
AL	NULL
ACKNOWLEDGMENT	NULL
We	NULL
thank	NULL
Dr	NULL
R.W	NULL
.	NULL

Karr	NULL
,	NULL
Prof	NULL
G.B	NULL
.	NULL

Ferrara	NULL
,	NULL
and	NULL
Dr	NULL
M.P	NULL
.	NULL

Pistillo	NULL
for	NULL
providing	NULL
the	NULL
DR-transfected	NULL
fibroblasts	NULL
,	NULL
Dr	NULL
MT	NULL
.	NULL

Ilieni	NULL
for	NULL
se-rologic	NULL
HLA	NULL
typing	NULL
,	NULL
Dr	NULL
F.	NULL
Poli	NULL
for	NULL
genomic	NULL
HLA	NULL
typing	NULL
,	NULL
and	NULL
Edoardo	NULL
Marchesi	NULL
for	NULL
dedicated	NULL
and	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Rowley	NULL
JD	NULL
,	NULL
Golomb	NULL
HM	NULL
,	NULL
Dougherty	NULL
C	NULL
:	NULL
15/17	NULL
translocation	NULL
,	NULL
a	NULL
consistent	NULL
chromosomal	NULL
change	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

Lancet	NULL
1:549	NULL
,	NULL
1977	NULL
2	NULL
.	NULL

Borrow	NULL
J	NULL
,	NULL
Goddard	NULL
AD	NULL
,	NULL
Sheer	NULL
D	NULL
,	NULL
Solomon	NULL
E	NULL
:	NULL
Molecular	NULL
analysis	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
breakpoint	NULL
cluster	NULL
region	NULL
on	NULL
chromosome	NULL
17	NULL
.	NULL

Science	NULL
249:1577	NULL
,	NULL
1990	NULL
3.	NULL
deThe	NULL
H	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
Lanotte	NULL
M	NULL
,	NULL
Degos	NULL
L	NULL
,	NULL
Dejean	NULL
A	NULL
:	NULL
The	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukaemia	NULL
fuses	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
gene	NULL
to	NULL
a	NULL
novel	NULL
transcribed	NULL
locus	NULL
.	NULL

Nature	NULL
347:558	NULL
,	NULL
1990	NULL
4	NULL
.	NULL

Pandolf	NULL
PP	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Alcalay	NULL
M	NULL
,	NULL
Mencarelli	NULL
A	NULL
,	NULL
Biondi	NULL
A	NULL
,	NULL
LoCoco	NULL
F	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
Structure	NULL
and	NULL
origin	NULL
of	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
myl/RARa	NULL
cDNA	NULL
and	NULL
characterization	NULL
of	NULL
its	NULL
retinoic-binding	NULL
and	NULL
transactivation	NULL
properties	NULL
.	NULL

Oncogene	NULL
6:1285	NULL
,	NULL
1991	NULL
5	NULL
.	NULL

Petkovich	NULL
M	NULL
,	NULL
Brand	NULL
NJ	NULL
,	NULL
Krust	NULL
A	NULL
,	NULL
Chambon	NULL
P	NULL
:	NULL
A	NULL
human	NULL
retinoic	NULL
acid	NULL
receptor	NULL
which	NULL
belongs	NULL
to	NULL
the	NULL
family	NULL
of	NULL
nuclear	NULL
receptors	NULL
.	NULL

Nature	NULL
330:444	NULL
,	NULL
1987	NULL
6	NULL
.	NULL

Healy	NULL
F	NULL
,	NULL
Drouet	NULL
C	NULL
,	NULL
Romer	NULL
P	NULL
,	NULL
Jaulin	NULL
C	NULL
,	NULL
Maryanski	NULL
JL	NULL
:	NULL
Conversion	NULL
of	NULL
a	NULL
self	NULL
peptide	NULL
sequence	NULL
into	NULL
a	NULL
K*-restricted	NULL
neoantigen	NULL
by	NULL
Tyr	NULL
substitution	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
174:1657	NULL
,	NULL
1991	NULL
7	NULL
.	NULL

Schumacher	NULL
TNM	NULL
,	NULL
De	NULL
Bruijn	NULL
MLH	NULL
,	NULL
Vernie	NULL
LN	NULL
,	NULL
Kast	NULL
WM	NULL
,	NULL
Melief	NULL
CJ	NULL
,	NULL
Neefjes	NULL
JJ	NULL
,	NULL
Ploegh	NULL
HL	NULL
:	NULL
Peptide	NULL
selection	NULL
by	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
.	NULL

Nature	NULL
350:703	NULL
,	NULL
1991	NULL
8	NULL
.	NULL

Rudensky	NULL
AY	NULL
,	NULL
Preston-Hurlburt	NULL
P	NULL
,	NULL
Hong	NULL
S-C	NULL
,	NULL
Barlow	NULL
A	NULL
,	NULL
Jane-way	NULL
CA	NULL
:	NULL
Sequence	NULL
analysis	NULL
of	NULL
peptides	NULL
bound	NULL
to	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
.	NULL

Nature	NULL
353:622	NULL
,	NULL
1991	NULL
9	NULL
.	NULL

Rotzschke	NULL
O	NULL
,	NULL
Falk	NULL
K	NULL
,	NULL
Deres	NULL
K	NULL
,	NULL
Schild	NULL
H	NULL
,	NULL
Norda	NULL
M	NULL
,	NULL
Metzger	NULL
J	NULL
,	NULL
Jung	NULL
G	NULL
,	NULL
Rammensee	NULL
HG	NULL
:	NULL
Isolation	NULL
and	NULL
analysis	NULL
of	NULL
naturally	NULL
processed	NULL
viral	NULL
peptides	NULL
as	NULL
recognized	NULL
by	NULL
cytotoxic	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
348	NULL
:	NULL
252	NULL
,	NULL
1990	NULL
10	NULL
.	NULL

Madden	NULL
DR	NULL
,	NULL
Gorga	NULL
JC	NULL
,	NULL
Strominger	NULL
JL	NULL
,	NULL
Wiley	NULL
DC	NULL
:	NULL
The	NULL
structure	NULL
of	NULL
HLA-B27	NULL
reveals	NULL
nonamer	NULL
self-peptides	NULL
bound	NULL
in	NULL
an	NULL
extended	NULL
conformation	NULL
.	NULL

Nature	NULL
353:321	NULL
,	NULL
1991	NULL
11	NULL
.	NULL

Jung	NULL
S	NULL
,	NULL
Schluesener	NULL
HJ	NULL
:	NULL
Human	NULL
T	NULL
lymphocytes	NULL
recognize	NULL
a	NULL
peptide	NULL
of	NULL
single	NULL
point-mutated	NULL
,	NULL
oncogenic	NULL
ras	NULL
proteins	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
173:273	NULL
,	NULL
1991	NULL
12	NULL
.	NULL

Chen	NULL
W	NULL
,	NULL
Peace	NULL
DJ	NULL
,	NULL
Rovira	NULL
DK	NULL
,	NULL
You	NULL
S-G	NULL
,	NULL
Cheever	NULL
MA	NULL
:	NULL
T-cell	NULL
immunity	NULL
to	NULL
the	NULL
joining	NULL
region	NULL
of	NULL
p210°C~*®~	NULL
protein	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
89:1468	NULL
,	NULL
1992	NULL
13	NULL
.	NULL

Giphart	NULL
MG	NULL
,	NULL
Verduijn	NULL
W	NULL
:	NULL
;	NULL
The	NULL
eurotransplant	NULL
HLA-DRB	NULL
oli-gonucleotide	NULL
typing	NULL
set	NULL
.	NULL

Eur	NULL
J	NULL
Immunogen	NULL
18:57	NULL
,	NULL
1991	NULL
14	NULL
.	NULL

Miller	NULL
AD	NULL
,	NULL
Rosman	NULL
GJ	NULL
:	NULL
Improved	NULL
retroviral	NULL
vectors	NULL
for	NULL
gene	NULL
transfer	NULL
and	NULL
expression	NULL
.	NULL

Biotecniques	NULL
7:980	NULL
,	NULL
1989	NULL
15	NULL
.	NULL

Miller	NULL
AD	NULL
,	NULL
Trauber	NULL
DR	NULL
,	NULL
Buttimore	NULL
C	NULL
:	NULL
Factors	NULL
involved	NULL
in	NULL
production	NULL
of	NULL
helper	NULL
virus-free	NULL
retrovirus	NULL
vectors	NULL
.	NULL

Somat	NULL
Cell	NULL
Mol	NULL
Genet	NULL
12:175	NULL
,	NULL
1986	NULL
16	NULL
.	NULL

Mann	NULL
R	NULL
,	NULL
Mulligan	NULL
RC	NULL
,	NULL
Baltimore	NULL
D	NULL
:	NULL
Construction	NULL
of	NULL
a	NULL
retrovirus	NULL
packaging	NULL
mutant	NULL
and	NULL
its	NULL
use	NULL
to	NULL
produce	NULL
helper-free	NULL
defective	NULL
retrovirus	NULL
.	NULL

Cell	NULL
33:153	NULL
,	NULL
1983	NULL
17	NULL
.	NULL

Miller	NULL
AD	NULL
,	NULL
Buttimore	NULL
C	NULL
:	NULL
Redesign	NULL
of	NULL
retrovirus	NULL
packaging	NULL
cell	NULL
lines	NULL
to	NULL
avoid	NULL
recombination	NULL
leading	NULL
to	NULL
helper	NULL
virus	NULL
production	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
6:2895	NULL
,	NULL
1986	NULL
18	NULL
.	NULL

Pelicci	NULL
G	NULL
,	NULL
Lanfrancone	NULL
L	NULL
,	NULL
Grignani	NULL
Fr	NULL
,	NULL
McGlade	NULL
J	NULL
,	NULL
Cevallo	NULL
F	NULL
,	NULL
Forni	NULL
G	NULL
,	NULL
Nicolette	NULL
I	NULL
,	NULL
Grignani	NULL
F	NULL
,	NULL
Paxson	NULL
T	NULL
,	NULL
Pelicci	NULL
PG	NULL
:	NULL
A	NULL
novel	NULL
transforming	NULL
protein	NULL
with	NULL
a	NULL
SH2	NULL
domain	NULL
is	NULL
implicated	NULL
in	NULL
mitogenic	NULL
signal	NULL
transduction	NULL
.	NULL

Cell	NULL
70:1	NULL
,	NULL
1992	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

IMMUNOGENICITY	NULL
OF	NULL
THE	NULL
pmIl/RAR	NULL
«	NULL
FUSION	NULL
PROTEIN	NULL
a	NULL
19	NULL
.	NULL

Gaub	NULL
MP	NULL
,	NULL
Lutz	NULL
Y	NULL
,	NULL
Ruberte	NULL
E	NULL
,	NULL
Petkovich	NULL
M	NULL
,	NULL
Brand	NULL
N	NULL
,	NULL
Chambon	NULL
P	NULL
:	NULL
Antibodies	NULL
specific	NULL
to	NULL
the	NULL
retinoic	NULL
acid	NULL
human	NULL
nuclear	NULL
receptors	NULL
a	NULL
and	NULL
8	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
86:3089	NULL
,	NULL
1989	NULL
20	NULL
.	NULL

Clohe	NULL
EP	NULL
,	NULL
Watts	NULL
R	NULL
,	NULL
Bahl	NULL
M	NULL
,	NULL
Alber	NULL
C	NULL
,	NULL
Yu	NULL
W-Y	NULL
,	NULL
Anderson	NULL
R	NULL
,	NULL
Silver	NULL
J	NULL
,	NULL
Gregersen	NULL
PK	NULL
,	NULL
Karr	NULL
RW	NULL
:	NULL
Analysis	NULL
of	NULL
the	NULL
molecular	NULL
speci-ficities	NULL
of	NULL
anti-class	NULL
II	NULL
monoclonal	NULL
antibodies	NULL
by	NULL
using	NULL
L	NULL
cell	NULL
transfectants	NULL
expressing	NULL
HLA	NULL
class	NULL
II	NULL
molecules	NULL
.	NULL

J	NULL
Immunol	NULL
141:2158	NULL
,	NULL
1988	NULL
21	NULL
.	NULL

Taswell	NULL
C	NULL
,	NULL
MacDonald	NULL
HR	NULL
,	NULL
Cerottini	NULL
J-C	NULL
:	NULL
Clonal	NULL
analysis	NULL
of	NULL
cytolytic	NULL
T	NULL
lymphocyte	NULL
specificity	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
151:1372	NULL
,	NULL
1980	NULL
22	NULL
.	NULL

Gambacorti-Passerini	NULL
C	NULL
,	NULL
Rivoltini	NULL
L	NULL
,	NULL
Supino	NULL
R	NULL
,	NULL
Rodolfo	NULL
M	NULL
,	NULL
Radrizzani	NULL
M	NULL
,	NULL
Fossati	NULL
G	NULL
,	NULL
Parmiani	NULL
G	NULL
:	NULL
Susceptibility	NULL
of	NULL
chemoresistant	NULL
murine	NULL
and	NULL
human	NULL
tumor	NULL
cells	NULL
to	NULL
lysis	NULL
by	NULL
interleukin	NULL
2-activated	NULL
lymphocytes	NULL
.	NULL

Cancer	NULL
Res	NULL
48:2372	NULL
,	NULL
1988	NULL
23	NULL
.	NULL

Germain	NULL
RN	NULL
:	NULL
The	NULL
second	NULL
class	NULL
story	NULL
.	NULL

Nature	NULL
353:605	NULL
,	NULL
1991	NULL
24	NULL
.	NULL

Neefjes	NULL
JJ	NULL
,	NULL
Ploegh	NULL
HL	NULL
:	NULL
Intracellular	NULL
transport	NULL
of	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
.	NULL

Immunol	NULL
Today	NULL
13:179	NULL
,	NULL
1992	NULL
1375	NULL
25	NULL
.	NULL

Schild	NULL
H	NULL
,	NULL
Norda	NULL
M	NULL
,	NULL
Deres	NULL
K	NULL
,	NULL
Falk	NULL
K	NULL
,	NULL
Rotzschke	NULL
O	NULL
,	NULL
Wiesmiiller	NULL
K-H	NULL
,	NULL
Jung	NULL
G	NULL
,	NULL
Rammensee	NULL
HG	NULL
:	NULL
Fine	NULL
specificity	NULL
of	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
primed	NULL
in	NULL
vivo	NULL
with	NULL
virus	NULL
or	NULL
synthetic	NULL
lipopeptide	NULL
vaccine	NULL
or	NULL
primed	NULL
in	NULL
vitro	NULL
with	NULL
peptide	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
174:1665	NULL
,	NULL
1991	NULL
26	NULL
.	NULL

Castaigne	NULL
S	NULL
,	NULL
Chomienne	NULL
C	NULL
,	NULL
Ballerini	NULL
P	NULL
,	NULL
Berger	NULL
R	NULL
,	NULL
Fenaux	NULL
P	NULL
,	NULL
Degos	NULL
L	NULL
:	NULL
All-trans	NULL
retinoic	NULL
acid	NULL
as	NULL
a	NULL
differentiation	NULL
therapy	NULL
for	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
.	NULL

I	NULL
.	NULL

Clinical	NULL
results	NULL
.	NULL

Blood	NULL
76:1704	NULL
,	NULL
1990	NULL
27	NULL
.	NULL

Van	NULL
der	NULL
Bruggen	NULL
P	NULL
,	NULL
Traversari	NULL
C	NULL
,	NULL
Chomez	NULL
P	NULL
,	NULL
Lurquin	NULL
C	NULL
,	NULL
De	NULL
Plaen	NULL
E	NULL
,	NULL
Van	NULL
den	NULL
Eynde	NULL
B	NULL
,	NULL
Knuth	NULL
A	NULL
,	NULL
Boon	NULL
T	NULL
:	NULL
A	NULL
gene	NULL
encoding	NULL
an	NULL
antigen	NULL
recognized	NULL
by	NULL
cytolytic	NULL
T	NULL
lymphocytes	NULL
on	NULL
a	NULL
human	NULL
mela-noma	NULL
.	NULL

Science	NULL
254:1643	NULL
,	NULL
1991	NULL
28	NULL
.	NULL

Gambacorti-Passerini	NULL
C	NULL
,	NULL
Sondel	NULL
PM	NULL
:	NULL
Problems	NULL
,	NULL
controversies	NULL
,	NULL
and	NULL
perspectives	NULL
on	NULL
the	NULL
clinical	NULL
use	NULL
of	NULL
interleukin-2	NULL
.	NULL

Curr	NULL
Opinion	NULL
Oncol	NULL
2	NULL
:	NULL
1139	NULL
,	NULL
1990	NULL
~	NULL
29	NULL
.	NULL

Quirt	NULL
IC	NULL
,	NULL
Tannock	NULL
IF	NULL
:	NULL
Interleukin-2	NULL
for	NULL
metastatic	NULL
melanoma	NULL
:	NULL
Treating	NULL
polyuria	NULL
with	NULL
insulin	NULL
?	NULL

J	NULL
Clin	NULL
Oncol	NULL
8:1	NULL
125	NULL
,	NULL
1990	NULL
From	NULL
www	NULL
.	NULL

by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
Human	NULL
CD4	NULL
lymphocytes	NULL
specifically	NULL
recognize	NULL
a	NULL
peptide	NULL
representing	NULL
the	NULL
fusion	NULL
region	NULL
of	NULL
the	NULL
hybrid	NULL
protein	NULL
pmIl/RAR	NULL
alpha	NULL
present	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
cells	NULL
A	NULL
_	NULL
G	NULL
,	NULL
%	NULL
p	NULL
'	NULL
¢	NULL
\se	NULL
@	NULL
.	NULL

@	NULL
``	NULL
Q1oNT	NULL
(	NULL
f	NULL
@	NULL
C	NULL
Gambacorti-Passerini	NULL
,	NULL
F	NULL
Grignani	NULL
,	NULL
F	NULL
Arienti	NULL
,	NULL
PP	NULL
Pandolfi	NULL
,	NULL
PG	NULL
Pelicci	NULL
and	NULL
G	NULL
Parmiani	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/81/5/1369.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

